Related references
Note: Only part of the references are listed.Developments in epidermal growth factor receptor-targeting therapy for solid tumors: Focus on matuzumab (EMD 72000)
Joan H. Schiller
CANCER INVESTIGATION (2008)
Immune activation by epidermal growth factor receptor-specific monoclonal antibody therapy for head and neck cancer
Andres Upez-Albaitero et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2007)
Tumor immune escape by the loss of homeostatic chemokine expression
Anclor Pivarcsi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Clinical implications of the mechanism of epidermal growth factor receptor inhibitors
John Marshall
CANCER (2006)
Epidermal growth factor receptor targeting in cancer
John Mendelsohn et al.
SEMINARS IN ONCOLOGY (2006)
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Hidetoshi Sumimoto et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
U Graeven et al.
BRITISH JOURNAL OF CANCER (2006)
Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy
A Muller et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment
T Kuroda et al.
CLINICAL CANCER RESEARCH (2005)
ERK1/2 regulates epidermal chemokine expression and skin inflammation
S Pastore et al.
JOURNAL OF IMMUNOLOGY (2005)
Immunobiology of head and neck cancer
TL Whiteside
CANCER AND METASTASIS REVIEWS (2005)
An epidermal growth factor receptor chimeric human-murine monoclonal antibody
J Harding et al.
DRUGS OF TODAY (2005)
Molecular therapy of head and neck cancer
H Modjtahedi
CANCER AND METASTASIS REVIEWS (2005)
Expression profiling identifies chemokine (C-C motif) ligand 18 as an independent prognostic indicator in gastric cancer
SY Leung et al.
GASTROENTEROLOGY (2004)
Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor
U Vanhoefer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
CCL2 (monocyte chemoattractant protein-1) and cancer
I Conti et al.
SEMINARS IN CANCER BIOLOGY (2004)
Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets
CJ Barnes et al.
CANCER AND METASTASIS REVIEWS (2003)
Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation
F Mascia et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Targeting epidermal growth factor receptor in head and neck cancer
AC Ford et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2003)
Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx
H Bier et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Involvement of chemokine receptors in breast cancer metastasis
A Müller et al.
NATURE (2001)
Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily - Role as anticancer agents
SB Noonberg et al.
DRUGS (2000)
Cutting edge:: The orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC)
B Homey et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
